- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT01034475
Study to Evaluate Safety, Tolerability, Maximum Tolerated Dose (MTD), Efficacy, and Pharmacokinetics (PKs) of CPI-613 Given Twice Weekly for Three Consecutive Weeks in Patients With Advanced Hematologic Malignancies
An Open Label, Dose-Escalation Study to Evaluate Safety, Tolerability, Maximum Tolerated Dose (MTD), Efficacy, and Pharmacokinetics (PKs) of CPI-613 Given Twice Weekly for Three Consecutive Weeks in Patients With Advanced Hematologic Malignancies
Chemotherapy resistance is a major cause of death in patients with advanced hematologic malignancies. The proposed novel mechanism of action, non-cross resistance with chemotherapeutic agents currently used in the clinic, and lack of CPI-613-related myelosuppression preclinically and clinically to date make CPI-613 a suitable candidate for phase I clinical trial in these patients. The current trial is one of several clinical trials of CPI-613. Other clinical trials that are conducted in patients with solid tumors have already been initiated.
The primary objective of this study is to determine the safety and MTD of CPI-613 when administered 2x weekly for 3 consecutive weeks.
The secondary objective is to determine the PKs of CPI-613 following IV administration and to observe the anti-tumor effects of CPI-613, if any occur.
Studieoversikt
Status
Intervensjon / Behandling
Studietype
Registrering (Faktiske)
Fase
- Fase 1
Kontakter og plasseringer
Studiesteder
-
-
North Carolina
-
Winston-Salem, North Carolina, Forente stater, 27012
- Wake Forest University Health Sciences
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- histologically or cytologically documented relapsed and/or refractory hematologic malignancy
- Karnofsky Performance Status (KPS) of >70%.
- Must be ≥18 years of age.
- Expected survival >1 month.
- Women of child-bearing potential must use accepted contraceptive methods
- No radiotherapy, treatment with cytotoxic agents (except CPI-613), treatment with biologic agents or any anti-cancer therapy within the 3 weeks prior to treatment with CPI-613.
Exclusion Criteria:
- Serious medical illness, such as significant cardiac disease (e.g. symptomatic congestive heart failure, unstable angina pectoris, myocardial infarction within the past 6 months, uncontrolled cardiac arrhythmia, or New York Heart Association Class III or IV), or severe debilitating pulmonary disease, that would potentially increase patients' risk for toxicity.
- Patients with active central nervous system (CNS) or epidural tumor.
- Any active uncontrolled bleeding, and any patients with a bleeding diathesis (e.g., active peptic ulcer disease).
- Pregnant women, or women of child-bearing potential not using reliable means of contraception.
- Lactating females because the potential of excretion of CPI-613 into breast milk.
- Life expectancy less than 1 month.
- Any condition or abnormality which may, in the opinion of the investigator, compromise the safety of patients.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Eksperimentell: CPI-613
CPI-240 mg/m2
|
This is a Phase I open label trial using a 2-stage dose-escalation scheme (single-patient & traditional stages): Single-Patient Dose-Escalation Stage: In the single-patient stage, a single patient will be accrued per dose level. The starting dose will be 420 mg/m². Dose level will be escalated (by doubling the previous dose) if there is no toxicity or if the toxicity is grade 1 or less. If toxicity is >Grade 1, the traditional dose-escalation stage will be triggered. Traditional Dose-Escalation: All dose escalations conducted in this Traditional Dose-Escalation stage will be escalated according to the modified Fibonacci Dose-Escalation scheme. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
---|---|
To determine the safety and MTD of CPI-613 when administered 2x weekly for 3 consecutive weeks.
Tidsramme: 3 weeks
|
3 weeks
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
---|---|
To determine PKs of CPI-613 following IV administration.
Tidsramme: 3 weeks
|
3 weeks
|
Samarbeidspartnere og etterforskere
Publikasjoner og nyttige lenker
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- IRB00012124
- CCCWFU 29109 (Annen identifikator: Wake Forest University Health Sciences)
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Avanserte hematologiske maligniteter
-
Providence Health & ServicesTilgjengeligKRAS G12V Mutant Advanced Epithelial Cancers
-
Novartis PharmaceuticalsFullførtcMET Dysegulation Advanced Solid TumorsØsterrike, Danmark, Sverige, Storbritannia, Spania, Tyskland, Nederland, Forente stater
-
Shanghai Pudong HospitalUTC Therapeutics Inc.TilbaketrukketMesothelin-positive Advanced Refractory Solid TumorsKina
-
Suzhou Zelgen Biopharmaceuticals Co.,LtdRekrutteringKRAS G12C Mutant Advanced Solid TumorsKina
-
AZ-VUBAstraZeneca; Kom Op Tegen KankerRekrutteringAdvanced Cancers Harboring Mutations in HRGBelgia
-
AmgenAktiv, ikke rekrutterendeKRAS p.G12C Mutant Advanced Solid TumorsForente stater, Frankrike, Canada, Spania, Belgia, Korea, Republikken, Østerrike, Australia, Ungarn, Hellas, Tyskland, Japan, Romania, Sveits, Brasil, Portugal
-
Agenus Inc.FullførtAvansert solid kreft | Advanced Solid Cancers Refractory to PD-1Forente stater
-
Yongchang ZhangRekrutteringHER2 Insertion Mutation Positive Advanced NSCLCKina
-
Extremity MedicalRekrutteringArtrose | Inflammatorisk leddgikt | Karpaltunnelsyndrom (CTS) | Posttraumatisk leddgikt | Scapholunate Advanced Collapse (SLAC) | Scapholunate Crystalline Advanced Collapse (SCAC) | Scaphoid, Trapesium og Trapesoid Advanced Collapse (STTAC) | Kienbocks sykdom hos voksne | Radial Malunion | Ulnar Translokasjon og andre forholdForente stater
-
Ottawa Hospital Research InstituteFullførtUnderstreke | Kriseressurshåndtering (CRM) ferdigheter | Advanced Cardiovascular Life Support (ACLS) ferdigheterCanada
Kliniske studier på CPI-613
-
Memorial Sloan Kettering Cancer CenterM.D. Anderson Cancer Center; Massachusetts General Hospital; City of Hope... og andre samarbeidspartnereAktiv, ikke rekrutterende
-
Cornerstone PharmaceuticalsFullførtLymfom | Metastatisk kreft | Avansert kreft | Solide svulster | Avanserte maligniteterForente stater, Canada
-
Medical College of WisconsinBarbara Ann Karmanos Cancer Institute; Cornerstone PharmaceuticalsRekrutteringBukspyttkjertel AdenokarsinomForente stater
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Cornerstone PharmaceuticalsTilbaketrukketDuktalt adenokarsinom i bukspyttkjertelen
-
Cornerstone PharmaceuticalsTilbaketrukketAkutt myeloid leukemi (AML) | Myelodysplastisk syndrom (MDS)Forente stater
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)FullførtAvansert primær leverkreft hos voksne | Lokalisert ikke-opererbar primær leverkreft hos voksne | Tilbakevendende primær leverkreft hos voksne | Tilbakevendende ekstrahepatisk gallekanalkreft | Ikke-opererbar ekstrahepatisk gallekanalkreft | Kolangiokarsinom i den ekstrahepatiske gallekanalen | Kolangiokarsinom... og andre forholdForente stater
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)FullførtAcinarcelleadenokarsinom i bukspyttkjertelen | Kanalcelleadenokarsinom i bukspyttkjertelen | Tilbakevendende kreft i bukspyttkjertelen | Stadium III Bukspyttkjertelkreft | Stadium IV BukspyttkjertelkreftForente stater
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)AvsluttetTidligere behandlede myelodysplastiske syndromerForente stater
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)FullførtTilbakevendende småcellet lungekreftForente stater
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)TilbaketrukketCPI-613 og Docetaxel ved behandling av pasienter med stadium IIIB eller IV ikke-småcellet lungekreftStage IV ikke-småcellet lungekreft AJCC v7 | Stadium IIIB ikke-småcellet lungekreft AJCC v7Forente stater